Received Feb 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 7LC49 | — |
redness of the skin between the injection location and my armpit; This non-serious case was reported by a consumer and described the occurrence of erythema of extremities in a 51-year-old male patient who received Herpes zoster (Shingrix) (batch number X5T42, expiry date 30-JAN-2027) and (batch number 7LC49) for prophylaxis. Concurrent medical conditions included hypertension and back pain. Concomitant products included gabapentin, losartan and meloxicam. On 14-FEB-2025, the patient received the 2nd dose of Shingrix .5 ml. On 16-FEB-2025, 2 days after receiving Shingrix, the patient experienced erythema of extremities (Verbatim: redness of the skin between the injection location and my armpit). The outcome of the erythema of extremities was not resolved. It was unknown if the reporter considered the erythema of extremities to be related to Shingrix. It was unknown if the company considered the erythema of extremities to be related to Shingrix. Additional Information: GSK Receipt Date 17-FEB-2025 The patient received Shingrix and on the day of reporting noticed some redness of the skin between the injection location and his armpit (redness).
Back pain; Hypertension
GABAPENTIN; LOSARTAN; MELOXICAM